The Current Ratio as of November 2024 (TTM) for Ikena Oncology, Inc. (IKNA) is 15.32

According to Ikena Oncology, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 15.32. This represents a change of -1.12% compared to the average of 15.49 of the last 4 quarters.

Ikena Oncology, Inc. (IKNA) Historical Current Ratio (quarterly & annually)

How has IKNA Current Ratio performed in the past?

The mean historical Current Ratio of Ikena Oncology, Inc. over the last ten years is 7.22. The current 15.32 Current Ratio has changed 21.12% with respect to the historical average. Over the past ten years (40 quarters), IKNA's Current Ratio was at its highest in in the June 2024 quarter at 18.22. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

Ikena Oncology, Inc. (IKNA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Ikena Oncology, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Ikena Oncology, Inc. (IKNA) Average Current Ratio

How has IKNA Current Ratio performed in the past?

The current Current Ratio of Ikena Oncology, Inc. (IKNA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Ikena Oncology, Inc. (IKNA) Current Ratio vs. Peers

How is IKNA’s Current Ratio compared to its peers?

Ikena Oncology, Inc.’s Current Ratio is less than Edgewise Therapeutics, Inc. (26.35), less than Design Therapeutics, Inc. (34.61), greater than Xilio Therapeutics, Inc. (1.67), less than Eliem Therapeutics, Inc. (60.41), greater than Monte Rosa Therapeutics, Inc. (6.03), greater than Werewolf Therapeutics, Inc. (10.10), greater than Stoke Therapeutics, Inc. (5.09), greater than Anebulo Pharmaceuticals, Inc. (3.45), greater than Celcuity Inc. (10.36), less than MediciNova, Inc. (16.66), greater than Rezolute, Inc. (13.79), greater than Aerovate Therapeutics, Inc. (8.78), greater than Decibel Therapeutics, Inc. (4.81), greater than Foghorn Therapeutics Inc. (4.77), greater than Shattuck Labs, Inc. (7.96), greater than Kymera Therapeutics, Inc. (8.55), greater than Nurix Therapeutics, Inc. (5.28),

Build a custom stock screener for Ikena Oncology, Inc. (IKNA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Ikena Oncology, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Ikena Oncology, Inc. (IKNA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Ikena Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.